Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease

Ilan S. Weisberg, Eric Park, Karla V. Ballman, Peter Berger, Martha E. Nunn, Daniel S. Suh, Andrew P. Breksa, Timothy A. Garrow, Rima Rozen

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Hyperhomocysteinemia, a risk factor for cardiovascular disease, can be caused by genetic mutations in enzymes of homocysteine metabolism. Homocysteine remethylation to methionine is catalyzed by folate-dependent methionine synthase, or by betaine-homocysteine methyltransferase (BHMT), which utilizes betaine as the methyl donor. Since genetic variants in folate-dependent remethylation have been reported to increase risk for cardiovascular disease and other common disorders, we screened BHMT for sequence changes that might alter risk for coronary artery disease (CAD). A variant in exon 6 - R239Q - was identified. The frequency of this change was examined in 504 individuals who had undergone coronary angiography and were stratified into controls (those with no or mild disease) and cases (those with significant [>50% reduction in luminal diameter stenosis] 1-, 2-, 3-vessel disease). Although this variant did not affect plasma homocysteine, the QQ genotype was present in higher frequency in those with no or mild disease, compared with those with significant disease (11 vs. 6%), suggesting that it may decrease risk of CAD; a statistically-significant decrease was seen in the older subjects (13 vs. 7%). Multivariate analysis for the entire group revealed an odds ratio of 0.48 (95% CI: 0.21-1.06) for the QQ genotype; this association was similar in the younger (OR=0.36; 95% CI: 0.09-1.41) and older subjects (OR=0.42; 95% CI: 0.15-1.18). Our study suggests that the Q allele of the R239Q mutation may decrease the risk of CAD and that this variant warrants additional investigation of its relationship with the development of CAD as well as other homocysteine-dependent disorders.

Original languageEnglish
Pages (from-to)205-214
Number of pages10
JournalAtherosclerosis
Volume167
Issue number2
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Betaine-Homocysteine S-Methyltransferase
Homocysteine
Coronary Artery Disease
Folic Acid
Cardiovascular Diseases
Genotype
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Betaine
Hyperhomocysteinemia
Mutation
Coronary Angiography
Methionine
Exons
Pathologic Constriction
Multivariate Analysis
Alleles
Odds Ratio
Enzymes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. / Weisberg, Ilan S.; Park, Eric; Ballman, Karla V.; Berger, Peter; Nunn, Martha E.; Suh, Daniel S.; Breksa, Andrew P.; Garrow, Timothy A.; Rozen, Rima.

In: Atherosclerosis, Vol. 167, No. 2, 01.04.2003, p. 205-214.

Research output: Contribution to journalArticle

Weisberg, IS, Park, E, Ballman, KV, Berger, P, Nunn, ME, Suh, DS, Breksa, AP, Garrow, TA & Rozen, R 2003, 'Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease', Atherosclerosis, vol. 167, no. 2, pp. 205-214. https://doi.org/10.1016/S0021-9150(03)00010-8
Weisberg, Ilan S. ; Park, Eric ; Ballman, Karla V. ; Berger, Peter ; Nunn, Martha E. ; Suh, Daniel S. ; Breksa, Andrew P. ; Garrow, Timothy A. ; Rozen, Rima. / Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. In: Atherosclerosis. 2003 ; Vol. 167, No. 2. pp. 205-214.
@article{dbc56a3603bd4694a2fc59ff3b7e54fc,
title = "Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease",
abstract = "Hyperhomocysteinemia, a risk factor for cardiovascular disease, can be caused by genetic mutations in enzymes of homocysteine metabolism. Homocysteine remethylation to methionine is catalyzed by folate-dependent methionine synthase, or by betaine-homocysteine methyltransferase (BHMT), which utilizes betaine as the methyl donor. Since genetic variants in folate-dependent remethylation have been reported to increase risk for cardiovascular disease and other common disorders, we screened BHMT for sequence changes that might alter risk for coronary artery disease (CAD). A variant in exon 6 - R239Q - was identified. The frequency of this change was examined in 504 individuals who had undergone coronary angiography and were stratified into controls (those with no or mild disease) and cases (those with significant [>50{\%} reduction in luminal diameter stenosis] 1-, 2-, 3-vessel disease). Although this variant did not affect plasma homocysteine, the QQ genotype was present in higher frequency in those with no or mild disease, compared with those with significant disease (11 vs. 6{\%}), suggesting that it may decrease risk of CAD; a statistically-significant decrease was seen in the older subjects (13 vs. 7{\%}). Multivariate analysis for the entire group revealed an odds ratio of 0.48 (95{\%} CI: 0.21-1.06) for the QQ genotype; this association was similar in the younger (OR=0.36; 95{\%} CI: 0.09-1.41) and older subjects (OR=0.42; 95{\%} CI: 0.15-1.18). Our study suggests that the Q allele of the R239Q mutation may decrease the risk of CAD and that this variant warrants additional investigation of its relationship with the development of CAD as well as other homocysteine-dependent disorders.",
author = "Weisberg, {Ilan S.} and Eric Park and Ballman, {Karla V.} and Peter Berger and Nunn, {Martha E.} and Suh, {Daniel S.} and Breksa, {Andrew P.} and Garrow, {Timothy A.} and Rima Rozen",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0021-9150(03)00010-8",
language = "English",
volume = "167",
pages = "205--214",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease

AU - Weisberg, Ilan S.

AU - Park, Eric

AU - Ballman, Karla V.

AU - Berger, Peter

AU - Nunn, Martha E.

AU - Suh, Daniel S.

AU - Breksa, Andrew P.

AU - Garrow, Timothy A.

AU - Rozen, Rima

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Hyperhomocysteinemia, a risk factor for cardiovascular disease, can be caused by genetic mutations in enzymes of homocysteine metabolism. Homocysteine remethylation to methionine is catalyzed by folate-dependent methionine synthase, or by betaine-homocysteine methyltransferase (BHMT), which utilizes betaine as the methyl donor. Since genetic variants in folate-dependent remethylation have been reported to increase risk for cardiovascular disease and other common disorders, we screened BHMT for sequence changes that might alter risk for coronary artery disease (CAD). A variant in exon 6 - R239Q - was identified. The frequency of this change was examined in 504 individuals who had undergone coronary angiography and were stratified into controls (those with no or mild disease) and cases (those with significant [>50% reduction in luminal diameter stenosis] 1-, 2-, 3-vessel disease). Although this variant did not affect plasma homocysteine, the QQ genotype was present in higher frequency in those with no or mild disease, compared with those with significant disease (11 vs. 6%), suggesting that it may decrease risk of CAD; a statistically-significant decrease was seen in the older subjects (13 vs. 7%). Multivariate analysis for the entire group revealed an odds ratio of 0.48 (95% CI: 0.21-1.06) for the QQ genotype; this association was similar in the younger (OR=0.36; 95% CI: 0.09-1.41) and older subjects (OR=0.42; 95% CI: 0.15-1.18). Our study suggests that the Q allele of the R239Q mutation may decrease the risk of CAD and that this variant warrants additional investigation of its relationship with the development of CAD as well as other homocysteine-dependent disorders.

AB - Hyperhomocysteinemia, a risk factor for cardiovascular disease, can be caused by genetic mutations in enzymes of homocysteine metabolism. Homocysteine remethylation to methionine is catalyzed by folate-dependent methionine synthase, or by betaine-homocysteine methyltransferase (BHMT), which utilizes betaine as the methyl donor. Since genetic variants in folate-dependent remethylation have been reported to increase risk for cardiovascular disease and other common disorders, we screened BHMT for sequence changes that might alter risk for coronary artery disease (CAD). A variant in exon 6 - R239Q - was identified. The frequency of this change was examined in 504 individuals who had undergone coronary angiography and were stratified into controls (those with no or mild disease) and cases (those with significant [>50% reduction in luminal diameter stenosis] 1-, 2-, 3-vessel disease). Although this variant did not affect plasma homocysteine, the QQ genotype was present in higher frequency in those with no or mild disease, compared with those with significant disease (11 vs. 6%), suggesting that it may decrease risk of CAD; a statistically-significant decrease was seen in the older subjects (13 vs. 7%). Multivariate analysis for the entire group revealed an odds ratio of 0.48 (95% CI: 0.21-1.06) for the QQ genotype; this association was similar in the younger (OR=0.36; 95% CI: 0.09-1.41) and older subjects (OR=0.42; 95% CI: 0.15-1.18). Our study suggests that the Q allele of the R239Q mutation may decrease the risk of CAD and that this variant warrants additional investigation of its relationship with the development of CAD as well as other homocysteine-dependent disorders.

UR - http://www.scopus.com/inward/record.url?scp=0038124366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038124366&partnerID=8YFLogxK

U2 - 10.1016/S0021-9150(03)00010-8

DO - 10.1016/S0021-9150(03)00010-8

M3 - Article

VL - 167

SP - 205

EP - 214

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -